HomeComparePFE vs HOLX

PFE vs HOLX: Dividend Comparison 2026

PFE yields 6.20% · HOLX yields 2.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $27.4K in total portfolio value· pulled ahead in Year 9
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
HOLX
HOLX
● Live price
2.65%
Share price
$75.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$314.03
Full HOLX calculator →

Portfolio growth — PFE vs HOLX

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFEHOLX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + HOLX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
HOLX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
HOLX
Annual income on $10K today (after 15% tax)
$225.02/yr
After 10yr DRIP, annual income (after tax)
$266.93/yr
At 15% tax rate, PFE beats the other by $22,862.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + HOLX for your $10,000?

PFE: 50%HOLX: 50%
100% HOLX50/50100% PFE
Portfolio after 10yr
$37.4K
Annual income
$13,762.28/yr
Blended yield
36.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HOLX right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
HOLX
Analyst Ratings
18
Buy
23
Hold
1
Sell
Consensus: Hold
Price Target
$77.80
+3.0% upside vs current
Range: $76.00 — $79.00
Altman Z
4.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
HOLX buys
0
No recent congressional trades found for PFE or HOLX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFEHOLX
Forward yield6.20%2.65%
Annual dividend / share$1.72$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%0%
Portfolio after 10y$51.1K$23.6K
Annual income after 10y$27,210.54$314.03
Total dividends collected$60.1K$2.9K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusHoldHold
Analyst price target$27.50$77.80

Year-by-year: PFE vs HOLX ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrHOLX PortfolioHOLX Income/yrGap
1$9,161$701.38$10,965$264.73$1.8KHOLX
2$8,610$859.79$12,004$271.27$3.4KHOLX
3$8,366$1,081.25$13,121$277.55$4.8KHOLX
4$8,483$1,405.66$14,323$283.54$5.8KHOLX
5$9,084$1,907.24$15,615$289.27$6.5KHOLX
6$10,418$2,732.78$17,003$294.73$6.6KHOLX
7$13,007$4,193.56$18,493$299.93$5.5KHOLX
8$18,010$7,005.87$20,093$304.87$2.1KHOLX
9← crossover$28,216$12,979.89$21,809$309.57+$6.4KPFE
10$51,081$27,210.54$23,649$314.03+$27.4KPFE

PFE vs HOLX: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

HOLXHealthcare

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Full HOLX Calculator →
📬

Get this PFE vs HOLX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.